TUDCA
Best-in-class: TUDCA
A bile acid that supports liver and bile flow, reduces ER (endoplasmic-reticulum) stress, and is popular for liver protection — especially alongside oral compounds that stress the liver.
TUDCA quick facts
| Suggested dose | 250–500 mg daily; higher for active liver-protection protocols. |
| How often | Daily |
| Who it's for | Liver and bile support — a go-to during liver-stressing supplement/medication cycles. |
Genuine clinical use in cholestatic liver disease, and the ER-stress mechanism is one of the more interesting in this whole catalog. Popular for liver protection during oral compound use, which is mechanistically reasonable and not trial-tested for that purpose. Expensive. It can cause diarrhea at higher doses.
How TUDCA actually works
Tauroursodeoxycholic acid is a hydrophilic bile acid that displaces toxic hydrophobic bile acids from the hepatocyte membrane, reducing their detergent damage. It also reduces endoplasmic reticulum stress by acting as a chemical chaperone helping proteins fold correctly — a mechanism that extends well beyond the liver and is why it is studied in neurodegeneration.
Where to get TUDCA
Find TUDCA on iHerb →The evidence for TUDCA
Graded by what exists behind each claim.
✅ Clinically validated
- Clinical use for cholestatic liver conditions; improves bile flow and liver markers.
- Reduces ER stress and supports hepatocyte and even neuronal survival in studies.
📊 Correlative data
- Impaired bile flow tracks with liver stress and digestion problems.
🧪 Theoretical / extrapolated benefits
- Neuroprotective and metabolic roles are promising in early research.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What TUDCA actually does
Tauroursodeoxycholic acid is a bile acid, which means it is not dosed once and cleared. It is dosed once and then recycled six to ten times a day for as long as it stays in the pool. It is ursodeoxycholic acid conjugated to taurine, roughly 500 daltons, and the conjugation is what keeps it ionized and trapped in the intestinal lumen until a specific transporter collects it.
The transporter is the clock. Conjugated bile acids are reabsorbed almost entirely in the terminal ileum by the apical sodium-dependent bile acid transporter, returned to the liver in portal blood, and secreted back into bile. That loop turns over with each meal, which is why bile acid physiology is measured in enterohepatic cycles rather than in half-lives Eusufzai 1995. What escapes the ileum reaches the colon and is lost, which is the same step that produces diarrhea when the loop is broken Ruiz-Campos 2019.
Two mechanisms sit on top of that loop and they are different sizes. The bile-flow mechanism is a hydrophilicity mechanism: adding a hydrophilic bile acid to the pool shifts the mixture away from the detergent-like species that damage membranes. The cell-biology mechanism is a chemical chaperone effect that reduces endoplasmic reticulum stress and the unfolded protein response, and that is the one the neurology trials are built on Lombardo 2023.
Which means the useful variable is enrichment of the pool, not a plasma peak. A single 500 mg capsule enters a circulating pool of roughly 2 to 4 g that cycles all day. Changing the composition of that pool is a days-to-weeks operation, and any page that describes this as acute liver protection taken before a stressor has described a pharmacology this molecule does not have.
Cell, rodent, human — and where it stops
Almost everything strong in this literature belongs to the unconjugated drug or to a fixed-dose combination, not to the supplement.
What has been measured in people. A randomized double-blind trial of tauroursodeoxycholic acid as add-on treatment in amyotrophic lateral sclerosis exists, with a published statistical analysis plan Lombardo 2023. A fixed combination of sodium phenylbutyrate with taurursodiol has been through a systematic review and meta-analysis in the same disease Jomaa 2026. And bile acid metabolites have been shown to predict multiple sclerosis progression, with supplementation reported as safe in progressive disease Ladakis 2024.
The first obstacle is that the combination is not the molecule. The meta-analyzed product contains a second active drug Jomaa 2026. Attributing its result to the bile acid alone is the commonest error made about this ingredient, and the trial design does not permit it.
The second obstacle is that the supplement claim is hepatic and the trials are neurological. The endoplasmic reticulum stress mechanism is shared, which is why the extrapolation is tempting Lombardo 2023. Nobody has randomized people taking hepatotoxic oral compounds to this bile acid and measured their liver enzymes, which is the trial the supplement market is behaving as though exists.
What would close the gap. Report the bile acid pool composition alongside the endpoint. Bile acid replacement work in short-bowel syndrome shows that pool composition can be manipulated and measured deliberately Gruy-Kapral 1999, which is the technique this literature needs and does not use.
TUDCA — which form, and does it matter
TUDCA and UDCA are one carbon-nitrogen bond apart and that bond changes where the molecule goes. Ursodeoxycholic acid is the licensed drug with decades of cholestatic-disease evidence. Adding taurine lowers the pKa, keeps the molecule ionized across the physiological pH range, and reduces passive absorption in the jejunum so that more of it reaches the ileal transporter Eusufzai 1995. Most of the strong clinical data belongs to the unconjugated form.
Conjugation also happens without help. The liver conjugates ursodeoxycholic acid with taurine and glycine anyway. So part of what a taurine-conjugated supplement buys is a step the body performs for free, and how much that is worth in a person with normal hepatic conjugation has not been quantified.
Taurursodiol is the third name for the same chemistry. The fixed-dose drug combination uses that term Jomaa 2026. A reader comparing a supplement label with a trial has to know that TUDCA, tauroursodeoxycholic acid and taurursodiol are the same substance, and that only one of the three arrives with a companion drug.
No filed panel for a vendor TUDCA product has been read into supplements_data.BLENDS. Purity is the live question in this category, and this page makes no claim about the content of any particular bottle.
What would have to be true, and how you would know it was not
1. The liver-panel prediction, at 8 weeks. Alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, alkaline phosphatase and bilirubin at baseline and 8 weeks. Predict that in a person with normal enzymes nothing moves much, because the cholestatic evidence base belongs to people who had cholestasis Ruiz-Campos 2019.
2. The prediction that cuts hardest against the marketing. In somebody taking an oral compound that raises liver enzymes, predict that adding this bile acid does not restore the panel to normal, because no trial has shown that and the mechanism does not require it Lombardo 2023. Treating a rising enzyme with a supplement rather than with a decision about the compound causing it is the actual risk on this page.
3. The timing prediction. Split the daily dose across meals for 4 weeks, then take the same total once daily away from food for 4 weeks. Predict better tolerance and greater pool enrichment on the split-with-meals schedule, because the enterohepatic loop is meal-driven Eusufzai 1995.
4. The dose-limiting prediction. Predict loose stools as the ceiling, appearing as unabsorbed bile acid reaches the colon, which is the same mechanism as bile acid diarrhea from any cause Ruiz-Campos 2019. That symptom is the practical upper bound and it arrives before anything else does.
5. The falsification of the combination inference. A trial of the bile acid alone against the fixed-dose combination in the same population. Prediction: the combination outperforms, because it contains a second active Jomaa 2026. If they are identical, the second drug is not contributing and the supplement inference is vindicated.
What nobody has tested yet
Nobody has run TUDCA for liver protection in the population that buys it. The randomized trials are in neurological disease Lombardo 2023 Ladakis 2024. There is no trial in people taking hepatotoxic oral compounds.
Nobody has separated the two actives in the licensed combination. The meta-analysis pools a product with two components Jomaa 2026 and no dismantling study exists.
Nobody has published pool-enrichment kinetics for oral TUDCA at supplement doses. Bile acid pools can be manipulated and measured Gruy-Kapral 1999; nobody has done it at 250 to 500 mg a day and reported how many days enrichment takes.
And nobody has followed multi-year use. The trials run months Ladakis 2024. Continuous daily bile acid supplementation over years is undescribed.
TUDCA — its own safety story, not its category's
The contraindication that belongs to this molecule specifically is biliary obstruction. A bile acid works by being secreted into bile and returning. If the duct is blocked, adding more of a detergent molecule to a system that cannot drain is the wrong direction, and this is one of the few supplement contraindications that follows unambiguously from the mechanism Eusufzai 1995.
The dose-limiting effect is diarrhea and it has a specific cause. Bile acid that escapes ileal reabsorption reaches the colon and drives secretion, which is the same physiology as bile acid malabsorption Ruiz-Campos 2019. It is a signal that the loop is saturated rather than that something is damaged.
Fat-soluble vitamin and drug absorption can shift. Anything that changes bile composition changes micellar solubilization, so vitamins A, D, E and K and lipophilic drugs are the plausible interactions. This is a reason to space it from a fat-soluble multivitamin rather than a reason to avoid it.
The honest limit is the record's length. Most of the strong evidence is for the unconjugated drug in defined liver diseases, and the supplement's own trials are months long Lombardo 2023 Jomaa 2026 Ladakis 2024. Anyone with a known liver condition should be making this decision with the clinician who is monitoring it. Nothing here is medical advice or a diagnosis, and none of these statements has been evaluated by the Food and Drug Administration.
Sources read for this page
- Lombardo FL. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. Trials 2023 · PMID 38053196
- Ladakis DC. Bile acid metabolites predict multiple sclerosis progression and supplementation is safe in progressive disease. Med 2024 · PMID 39447576
- Jomaa AM. Efficacy of Sodium Phenylbutyrate-Taurursodiol in Amyotrophic Lateral Sclerosis: A Systematic Review and Meta-Analysis. Ann Indian Acad Neurol 2026 · PMID 42301686
- Eusufzai S. Bile acid malabsorption: mechanisms and treatment. Dig Dis 1995 · PMID 8542666
- Ruiz-Campos L. Systematic review with meta-analysis: the prevalence of bile acid malabsorption and response to colestyramine in patients with chronic watery diarrhoea and previous cholecystectomy.. Aliment Pharmacol Ther 2019 · PMID 30585336
- Gruy-Kapral C. Conjugated bile acid replacement therapy for short-bowel syndrome.. Gastroenterology 1999 · PMID 9869597
How you would know if it worked
These are the markers that recommend this product on their own pages, so they are the ones that should move if it is doing what it is sold for.
- Enhanced Liver Fibrosis (ELF) Test — Omega-3s, TUDCA, and adequate choline support hepatic fat export Retest: Annually if elevated or at risk.
- Comprehensive Metabolic Panel (CMP) — Omega-3s, vitamin E (in NAFLD), TUDCA 250–500 mg (used by those on hepatotoxic orals), NAC, milk thistle (modest evidence) Retest: Every 3–6 months on any oral compound; annually otherwise.
- GGT (Gamma-Glutamyl Transferase) — TUDCA works on a different step — bile flow, the exit route — and is the sensible addition when the picture looks cholestatic Retest: 6 weeks minimum after any change, because of the 2–3 week half-life. Sooner than that and you are measuring the previous month. Every 6–12 months as routine if you drink, carry visceral fat, or run oral compounds.
The cheapest panel carrying Enhanced Liver Fibrosis (ELF) Test and at least one other of these is Fatty Liver & Liver Health, at $324 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
TUDCA — safety & side effects
- GI upset and diarrhea are the common effects.
- Avoid with bile duct obstruction — a bile acid with nowhere to go is a problem rather than a help.
- May affect absorption of fat-soluble vitamins and of some medications. Long-term safety has not been characterized — the trials run weeks to months, not years. That is a real limit on what anyone can tell you about daily use for a decade. Most of the strong data is for the related drug UDCA in specific liver diseases, not for TUDCA as a supplement.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — TUDCA in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside TUDCA
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| Comprehensive Metabolic Panel (CMP) | ALT, AST and bilirubin — the reason you're taking it, measured |
| Enhanced Liver Fibrosis (ELF) Test | Detects fibrosis that a normal ALT completely misses |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | Bile-acid handling and lipids move together |
The Fatty Liver & Liver Health panel covers these in one order — 8 markers, $291.15 with the discount applied.
Check results you already have → · All 103 markers A–Z
TUDCA — frequently asked questions
What is TUDCA?
A bile acid that supports liver and bile flow, reduces ER (endoplasmic-reticulum) stress, and is popular for liver protection — especially alongside oral compounds that stress the liver.
What is the suggested dose of TUDCA?
250–500 mg daily; higher for active liver-protection protocols. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find TUDCA dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy TUDCA?
Coach Cam sources TUDCA from vetted, top-rated brands on iHerb — use the buy link on this page.
TUDCA inside a finished plan
One arm of 3 Protocol Blueprints, free to read in full.
What TUDCA is used for
TUDCA appears under 3 goals in the goal router.
Related Immune & Detox supplements
Where this goes next
TUDCA is the digestive-output arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.